ArticleElectronic physician2018
Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial.
Article in Electronic physician, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Approach to headache disorders and the management of migraine: consensus guidelines from the Headache Society of Singapore, first edition (2023).Singapore medical journal · 2026Guideline
- Systematic Review Suggests Nutraceuticals Containing Vitamin B2 Could Provide an Alternative Treatment for Paediatric Migraines.Acta paediatrica (Oslo, Norway : 1992) · 2025Pooled it
- Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis.BMJ open · 2021Pooled it
- Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine Prophylaxis: A Systematic Review and Network Meta-analysis.JAMA pediatrics · 2020Pooled it
- Common Mechanisms in Migraine, Migraine-Related Neck Pain, and Low Back Pain: Implications for Treatment.Pain and therapy · 2026Review
- Biosynthesis, Regulation, and Biotechnological Production Strategies of Riboflavin (Vitamin BPharmaceuticals (Basel, Switzerland) · 2026Review
- Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms.Journal of clinical medicine · 2026Review
- The effect of riboflavin on the mean attack frequency, severity, and duration of migraine headaches: A systematic review and dose-response meta-analysis of clinical trials.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026Review
- Migraine Management in Japan: Current Approaches and Science Narrative Including an Evidence-based Review.Internal medicine (Tokyo, Japan) · 2026Review
- Preventive Medications in Pediatric Migraine: A Network Meta-Analysis.JAMA network open · 2024Article
- [Complementary and supplementary procedures in the treatment of headache].Schmerz (Berlin, Germany) · 2023Review
- Review
- Complementary and Integrative Medicines as Prophylactic Agents for Pediatric Migraine: A Narrative Literature Review.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimRiboflavin may have an acceptable effect on migraine among children. This study was carried out to determine the prophylactic effect of riboflavin on migraine in children.
methodsThis randomized clinical trial study was performed at Shahid Beheshti Hospital in Kashan, Iran from December 2012 to February 2015. Ninety children with migraine were allocated randomly into 3 groups (placebo, low-dose and high-dose riboflavin). The outcomes (frequency, intensity and duration of headaches) were measured at baseline and 12 weeks of medication in each group, and the decrease of them were compared. SPSS software version 16 was used for analysis of the data. Descriptive statistics, Chi-square, Fisher's exact and t-test were used for statistical analyses.
resultsThere was a significant decrease of migraine frequency (p=0.000) and mean duration (p=0.000) in the high-dose group compared with the placebo group. No significant reduction of frequency and mean duration of attacks were reported in the low-dose group compared to the placebo group (p=0.49 and p=0.69 respectively). There was no significant reduction of migraine intensity in the low-dose and high-dose groups compared to the placebo group (p=0.71 and p=0.74 respectively).
conclusionHigh-dose riboflavin is a safe, well tolerated, cost-effective method of prophylaxis for children with migraine.
trial registrationThe trial was registered at the Iranian Clinical Trial Registry with number IRCT2013020412361N1.
fundingThe study was supported by the Deputy of Research, Kashan University of Medical Sciences (grant number 91073).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.